The Role of Immunomodulatory Treatment in Success of ICSI in Patients With Autoimmune Thyroiditis

PHASE2CompletedINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

March 7, 2018

Primary Completion Date

September 15, 2023

Study Completion Date

January 20, 2024

Conditions
InfertilityAutoimmune Thyroiditis
Interventions
DRUG

Immunomodulatory

"Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.~Moreover, patients will receive a treatment course of immunomodulatory drugs for 3 -6 months before ICSI cycle:~1. Prednisnlone 40mg for 2 weeks to be lowered gradually till become 5mg after 6 weeks and to be continued~2. Hydroxychloroquine according to body weight, patients who develop hypersensitivity will be shifted to Azathioprin.~3. Immunoglobulins will be used in cases not responding to treatment."

DRUG

Thyroxine

"Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.~Patients will not receive immunomodulatory drugs"

Trial Locations (1)

Unknown

Aljazeera (Al Gazeera) hospital, Giza

All Listed Sponsors
lead

Aljazeera Hospital

OTHER

NCT03289403 - The Role of Immunomodulatory Treatment in Success of ICSI in Patients With Autoimmune Thyroiditis | Biotech Hunter | Biotech Hunter